^
Association details:
| Biomarker: | EML4-ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) + U0126 (MEK1 inhibitor, MEK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer
Published date:
05/22/2020
Excerpt:
Furthermore, an EML4‐ALK‐positive NSCLC xenograft model is applied for the purpose of evaluating whether PD‐L1 inhibitor synergistically potentiates the antitumor effects in vivo....we constructed the murine pro‐B cell line Ba/F3, which stably expresses the exogenous EML4‐ALK fusion gene. As expected, in the NSCLC xenograft model, we observed that CER plus PD‐L1 inhibitor treatment and the CER group both significantly attenuated tumor growth compared with the control...
DOI:
10.1111/cas.14397
